POLYCYTHEMIA VERA (PV)
Clinical trials for POLYCYTHEMIA VERA (PV) explained in plain language.
Never miss a new study
Get alerted when new POLYCYTHEMIA VERA (PV) trials appear
Sign up with your email to follow new studies for POLYCYTHEMIA VERA (PV), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Cheap arthritis drug could be new weapon against rare blood cancers
Disease control Recruiting nowThis study tests whether low-dose methotrexate (MTX), a safe and inexpensive drug used for decades in arthritis, can help people with certain blood cancers called myeloproliferative neoplasms (MPNs), including polycythemia vera, essential thrombocythemia, and myelofibrosis. Resea…
Matched conditions: POLYCYTHEMIA VERA (PV)
Phase: PHASE2 • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Disease control
Last updated May 26, 2026 07:26 UTC
-
New hope for blood disorder: experimental drug DISC-3405 enters phase 2 trial
Disease control Recruiting nowThis study tests an experimental drug called DISC-3405 in 60 adults with polycythemia vera, a condition where the body makes too many red blood cells. The goal is to see if the drug is safe and can reduce the need for blood removal (phlebotomy). Participants will receive increasi…
Matched conditions: POLYCYTHEMIA VERA (PV)
Phase: PHASE2 • Sponsor: Disc Medicine, Inc • Aim: Disease control
Last updated May 22, 2026 13:51 UTC
-
New hope for rare blood cancers: first human trial of PRT12396 begins
Disease control Recruiting nowThis early-stage study tests a new drug called PRT12396 in about 100 people with two rare blood cancers: polycythemia vera and myelofibrosis. The main goals are to find a safe dose and see if the drug can help control the disease. Participants must have a specific genetic mutatio…
Matched conditions: POLYCYTHEMIA VERA (PV)
Phase: PHASE1 • Sponsor: Prelude Therapeutics • Aim: Disease control
Last updated May 20, 2026 11:56 UTC
-
New hope for blood cancer patients: experimental drug targets resistant polycythemia vera
Disease control Recruiting nowThis study tests a new pill, flonoltinib maleate, in 60 adults with polycythemia vera (a blood disorder causing too many red blood cells) who have not responded to or cannot tolerate standard therapies. The goal is to see if the drug safely controls red blood cell levels without …
Matched conditions: POLYCYTHEMIA VERA (PV)
Phase: PHASE2 • Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd • Aim: Disease control
Last updated May 20, 2026 11:54 UTC
-
Desperate patients get early access to promising drug for multiple Life-Threatening conditions
Disease control AVAILABLEThis program offers early access to the drug ruxolitinib (INC424) for patients with serious or life-threatening conditions like myelofibrosis, severe COVID-19, and graft-versus-host disease who have no other treatment options. It is for people who cannot join a clinical trial and…
Matched conditions: POLYCYTHEMIA VERA (PV)
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 20, 2026 11:54 UTC
-
New registry aims to unlock secrets of rare blood cancers
Knowledge-focused Recruiting nowThis study is a long-term registry for people with myeloproliferative neoplasms (MPNs), a group of rare blood cancers. Researchers will collect health records, surveys, and insurance data from 5,000 participants over at least five years to understand how the disease progresses an…
Matched conditions: POLYCYTHEMIA VERA (PV)
Sponsor: MPN Research Foundation • Aim: Knowledge-focused
Last updated May 26, 2026 07:23 UTC